Na Feifei相关文献与解析，生知库 | 链接生命科学的每一步

Transcriptomic Determinants of Circulating Immunity Predict Immune-Related Adverse Events (irAEs) in Cancer Patients Receiving PD-1/PD-L1 Blockade

循环免疫的转录组决定因素可预测接受PD-1/PD-L1阻断治疗的癌症患者的免疫相关不良事件（irAEs）

You, Liting; Zhai, Jianzhao; Xin, Zhaodan; Na, Feifei; Wen, Yang; Li, Jin; Song, Jiajia; Bai, Ling; Zhou, Xiaohan; Ying, Binwu; Zhou, Juan

肿瘤

Acquired resistance to immunotherapy by physical barriers with cancer cell-expressing collagens in non-small cell lung cancer

非小细胞肺癌中癌细胞表达胶原蛋白形成的物理屏障导致对免疫疗法的获得性耐药

期刊:Proceedings of the National Academy of Sciences of the United States of America

影响因子:9.1

doi:10.1073/pnas.2500019122

Wang, Manli; Wang, Yiyun; Pan, Xiangyu; Wang, Bo; Wang, Yuying; Luo, Xiangmeng; Deng, Xiaofeng; Liu, Li; Chen, Xuelan; Zhai, Xiaoqian; Wu, Baohong; Zhang, Qi; Ren, Yifeng; Li, Jia; Li, Xiaoyu; Cao, Fujun; Yang, Yang; Deng, Xintong; Li, Runhong; Lu, Zhenghao; Tan, Ping; Chen, Jingyao; Li, Yan; Liu, Yanyang; Liu, Jiewei; Wang, Yuan; Deng, Hongxin; Su, Zhaoming; Wang, Weiya; Wang, Yongsheng; Yang, Shengyong; Zhao, Chengjian; Xue, Jianxin; Wei, Yuquan; Zhang, Kang; Na, Feifei; Liu, Yu; Chen, Chong

Circulating immunological transcriptomic profile identifies DDX3Y and USP9Y on the Y chromosome as promising biomarkers for predicting response to programmed death 1/programmed death ligand 1 blockade

循环免疫转录组学分析发现，Y染色体上的DDX3Y和USP9Y是预测程序性死亡受体1/程序性死亡配体1阻断疗法疗效的潜在生物标志物。

期刊:Chinese Medical Journal

影响因子:7.3

doi:10.1097/CM9.0000000000003403

You, Liting; Xin, Zhaodan; Na, Feifei; Chen, Min; Wen, Yang; Li, Jin; Song, Jiajia; Bai, Ling; Zhai, Jianzhao; Zhou, Xiaohan; Ying, Binwu; Zhou, Juan

Enhanced multi-omics analysis reveals a lncRNA signature with 12 RNA modifications to predict tumor heterogeneity and potential therapy in non-small cell lung cancer

增强型多组学分析揭示了一种包含12种RNA修饰的lncRNA特征，可用于预测非小细胞肺癌的肿瘤异质性和潜在治疗方法。

期刊:Discover Oncology

影响因子:2.9

doi:10.1007/s12672-025-03677-8

You, Hua; Fan, Mingyu; Yin, Limei; Na, Feifei; You, Liting

Protocol to generate genetically engineered organoid-initiated mouse models of esophageal cancer.

构建基因工程类器官诱导的食管癌小鼠模型的方案

期刊:STAR Protocols

影响因子:1.3

doi:10.1016/j.xpro.2025.104028

Wang Jian, Du Jiajia, Luo Xiangmeng, Guo Linjie, Li Xiang, Dong Ziling, Lu Zhenghao, Wan Xudong, Wang Lu, Liu Hongyu, Li He, Tan Ping, Ji Yanhong, Li Yuan, Li Yaxin, Yang Yushang, Yuan Yong, Chen Longqi, Hu Bing, Liu Yu, Na Feifei, Chen Chong

First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?

对于驱动基因阴性的转移性肺腺癌伴恶性胸腔积液，一线治疗方案是化疗联合免疫检查点抑制剂还是贝伐单抗？

期刊:Investigational New Drugs

影响因子:2.7

doi:10.1007/s10637-024-01424-4

Zhao, Yuanyuan; Mei, Ting; Na, Feifei; Tian, Xiaoman; Ao, Rui; Long, Xiangyu; Luo, Qiang; Duan, Ping; Zhu, Jiang; Wang, Yongsheng; Huang, Meijuan; Liu, Yongmei; Gong, Youling

Involved-field irradiation or elective-nodal irradiation in neoadjuvant chemo-radiotherapy for locally-advanced esophageal cancer: comprehensive analysis for dosimetry, treatment-related complications, impact on lymphocyte, patterns of failure and survival

局部晚期食管癌新辅助放化疗中受累野照射或选择性淋巴结照射：剂量学、治疗相关并发症、对淋巴细胞的影响、失败模式和生存率的综合分析

期刊:Frontiers in Oncology

影响因子:3.3

doi:10.3389/fonc.2023.1274924

Chen, Xianyan; Zhang, Yingjie; Zhou, Xiaojuan; Wang, Min; Na, Feifei; Zhou, Lin; Xu, Yong; Zou, Bingwen; Xue, Jianxin; Liu, Yongmei; Gong, Youling

Novel directions of precision oncology: circulating microbial DNA emerging in cancer-microbiome areas

精准肿瘤学的新方向：循环微生物DNA在癌症-微生物组领域的研究进展

期刊:Precision Clinical Medicine

影响因子:5

doi:10.1093/pcmedi/pbac005

You, Liting; Zhou, Juan; Xin, Zhaodan; Hauck, J Spencer; Na, Feifei; Tang, Jie; Zhou, Xiaohan; Lei, Zichen; Ying, Binwu

Organoid technology and applications in lung diseases: Models, mechanism research and therapy opportunities

类器官技术及其在肺部疾病中的应用：模型、机制研究和治疗机遇

期刊:Frontiers in Bioengineering and Biotechnology

影响因子:4.8

doi:10.3389/fbioe.2022.1066869

Chen, Jingyao; Na, Feifei

3D/类器官

发表日期：2022

文献求助收藏

Stem-like T cells in cancer immunotherapy: biology, regulation and therapeutic targeting

癌症免疫疗法中的干细胞样T细胞：生物学、调控和治疗靶向

Transcriptomic Determinants of Circulating Immunity Predict Immune-Related Adverse Events (irAEs) in Cancer Patients Receiving PD-1/PD-L1 Blockade

循环免疫的转录组决定因素可预测接受PD-1/PD-L1阻断治疗的癌症患者的免疫相关不良事件（irAEs）

Acquired resistance to immunotherapy by physical barriers with cancer cell-expressing collagens in non-small cell lung cancer

非小细胞肺癌中癌细胞表达胶原蛋白形成的物理屏障导致对免疫疗法的获得性耐药

Circulating immunological transcriptomic profile identifies DDX3Y and USP9Y on the Y chromosome as promising biomarkers for predicting response to programmed death 1/programmed death ligand 1 blockade

循环免疫转录组学分析发现，Y染色体上的DDX3Y和USP9Y是预测程序性死亡受体1/程序性死亡配体1阻断疗法疗效的潜在生物标志物。

Enhanced multi-omics analysis reveals a lncRNA signature with 12 RNA modifications to predict tumor heterogeneity and potential therapy in non-small cell lung cancer

增强型多组学分析揭示了一种包含12种RNA修饰的lncRNA特征，可用于预测非小细胞肺癌的肿瘤异质性和潜在治疗方法。

Protocol to generate genetically engineered organoid-initiated mouse models of esophageal cancer.

构建基因工程类器官诱导的食管癌小鼠模型的方案

First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?

对于驱动基因阴性的转移性肺腺癌伴恶性胸腔积液，一线治疗方案是化疗联合免疫检查点抑制剂还是贝伐单抗？

Involved-field irradiation or elective-nodal irradiation in neoadjuvant chemo-radiotherapy for locally-advanced esophageal cancer: comprehensive analysis for dosimetry, treatment-related complications, impact on lymphocyte, patterns of failure and survival

局部晚期食管癌新辅助放化疗中受累野照射或选择性淋巴结照射：剂量学、治疗相关并发症、对淋巴细胞的影响、失败模式和生存率的综合分析

Novel directions of precision oncology: circulating microbial DNA emerging in cancer-microbiome areas

精准肿瘤学的新方向：循环微生物DNA在癌症-微生物组领域的研究进展

Organoid technology and applications in lung diseases: Models, mechanism research and therapy opportunities

类器官技术及其在肺部疾病中的应用：模型、机制研究和治疗机遇